Prehospital Stroke Management Optimized by Use of Clinical Scoring vs Mobile Stroke Unit for Triage of Patients With Stroke: A Randomized Clinical Trial.


Journal

JAMA neurology
ISSN: 2168-6157
Titre abrégé: JAMA Neurol
Pays: United States
ID NLM: 101589536

Informations de publication

Date de publication:
01 12 2019
Historique:
pubmed: 4 9 2019
medline: 22 6 2021
entrez: 4 9 2019
Statut: ppublish

Résumé

Transferring patients with large-vessel occlusion (LVO) or intracranial hemorrhage (ICH) to hospitals not providing interventional treatment options is an unresolved medical problem. To determine how optimized prehospital management (OPM) based on use of the Los Angeles Motor Scale (LAMS) compares with management in a Mobile Stroke Unit (MSU) in accurately triaging patients to the appropriate hospital with (comprehensive stroke center [CSC]) or without (primary stroke center [PSC]) interventional treatment. In this randomized multicenter trial with 3-month follow-up, patients were assigned week-wise to one of the pathways between June 15, 2015, and November 15, 2017, in 2 regions of Saarland, Germany; 708 of 824 suspected stroke patients did not meet inclusion criteria, resulting in a study population of 116 adult patients. Patients received either OPM based on a standard operating procedure that included the use of the LAMS (cut point ≥4) or management in an MSU (an ambulance with vascular imaging, point-of-care laboratory, and telecommunication capabilities). The primary end point was the proportion of patients accurately triaged to either CSCs (LVO, ICH) or PSCs (others). A predefined interim analysis was performed after 116 patients of the planned 232 patients had been enrolled. Of these, 53 were included in the OPM group (67.9% women; mean [SD] age, 74 [11] years) and 63 in the MSU group (57.1% women; mean [SD] age, 75 [11] years). The primary end point, an accurate triage decision, was reached for 37 of 53 patients (69.8%) in the OPM group and for 63 of 63 patients (100%) in the MSU group (difference, 30.2%; 95% CI, 17.8%-42.5%; P < .001). Whereas 7 of 17 OPM patients (41.2%) with LVO or ICH required secondary transfers from a PSC to a CSC, none of the 11 MSU patients (0%) required such transfers (difference, 41.2%; 95% CI, 17.8%-64.6%; P = .02). The LAMS at a cut point of 4 or higher led to an accurate diagnosis of LVO or ICH for 13 of 17 patients (76.5%; 6 triaged to a CSC) and of LVO selectively for 7 of 9 patients (77.8%; 2 triaged to a CSC). Stroke management metrics were better in the MSU group, although patient outcomes were not significantly different. Whereas prehospital management optimized by LAMS allows accurate triage decisions for approximately 70% of patients, MSU-based management enables accurate triage decisions for 100%. Depending on the specific health care environment considered, both approaches are potentially valuable in triaging stroke patients. ClinicalTrials.gov identifier: NCT02465346.

Identifiants

pubmed: 31479116
pii: 2749168
doi: 10.1001/jamaneurol.2019.2829
pmc: PMC6724153
doi:

Banques de données

ClinicalTrials.gov
['NCT02465346']

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1484-1492

Commentaires et corrections

Type : CommentIn

Auteurs

Stefan A Helwig (SA)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Andreas Ragoschke-Schumm (A)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Lenka Schwindling (L)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Michael Kettner (M)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.
Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.

Safwan Roumia (S)

Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.

Johann Kulikovski (J)

Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.

Isabel Keller (I)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Matthias Manitz (M)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Daniel Martens (D)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Daniel Grün (D)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Silke Walter (S)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Martin Lesmeister (M)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Kira Ewen (K)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Jannik Brand (J)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Mathias Fousse (M)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Jil Kauffmann (J)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Valerie C Zimmer (VC)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Shrey Mathur (S)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Thomas Bertsch (T)

Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, Paracelsus Medical University, Nuremberg, Germany.

Jürgen Guldner (J)

Department of Neurology, Knappschaftsklinikum Saar, Püttlingen, Germany.

Achim Magull-Seltenreich (A)

Department of Neurology, Knappschaftsklinikum Saar, Püttlingen, Germany.

Andreas Binder (A)

Department of Neurology, Klinikum Saarbrücken, Saarbrücken, Germany.

Elmar Spüntrup (E)

Department of Radiology, Klinikum Saarbrücken, Saarbrücken, Germany.

Anastasios Chatzikonstantinou (A)

Department of Neurology, Caritas-Klinikum Saarbrücken St Theresia, Saarbrücken, Germany.

Oliver Adam (O)

Medizinische Klinik, Kreiskrankenhaus St Ingbert, St Ingbert, Germany.

Kai Kronfeld (K)

Interdisciplinary Centre for Clinical Trials (IZKS), Mainz, Germany.

Yang Liu (Y)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Christian Ruckes (C)

Interdisciplinary Centre for Clinical Trials (IZKS), Mainz, Germany.

Helmut Schumacher (H)

Statistical Consultant, Ingelheim, Germany.

Iris Q Grunwald (IQ)

Department of Neuroscience, Faculty of Medical Science, Postgraduate Medical Institute, Anglia Ruskin University, Chelmsford, Southend University Hospital, Southend-on-Sea, United Kingdom.

Umut Yilmaz (U)

Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.

Thomas Schlechtriemen (T)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.
Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.
Zweckverband für Rettungsdienst und Feuerwehralarmierung, Saar, Germany.

Wolfgang Reith (W)

Department of Neuroradiology, University Hospital of the Saarland, Homburg, Germany.

Klaus Fassbender (K)

Department of Neurology, University Hospital of the Saarland, Homburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH